RUO monalizumab是一种阻断抗体,可防止表达HLA-E的肿瘤细胞对CD 8 + T细胞和NK细胞的抑制。通过同时作用于先天免疫和适应性免疫,monalizumab可以重新建立广泛的抗肿瘤反应。 Monalizumab生物仿制药-研究级该产品同种型对照:Bulk Human IgG4 Isotype Control (IB4) [ICH2257] 缓冲液:ICH3002 浓度:5mg/ml 纯度:>95% by SDS-PAGE 内毒素:≤ 1.0 EU/mg as determined by the LAL method 制剂:Sterile, preservative-free, solution in PBS. BSA and Azide free.